Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • LinkedIn
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Arteriosclerosis, Thrombosis, and Vascular Biology

  • My alerts
  • Sign In
  • Join

  • Facebook
  • LinkedIn
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • ATVB Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Cover Art Award
    • ATVB Early Career Award
    • ATVB in Focus
    • Recent Brief Reviews of ATVB
    • Lecture Series
    • Collections
    • Recent Highlights of ATVB
    • Commentaries
    • Browse Abstracts
    • Insight into ATVB Authors
  • Resources
    • Instructions for Authors
    • Online Submission/Peer Review Site
    • Council on ATVB
    • Permissions and Rights Q&A
    • AHA Guidelines and Statements
    • Customer Service and Ordering Information
    • Author Reprints
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Clinical and Population Studies

Coronary Artery Calcification in Hemophilia A

No Evidence for a Protective Effect of Factor VIII Deficiency on Atherosclerosis

Attie Tuinenburg, Annemarieke Rutten, Maryam Kavousi, Frank W.G. Leebeek, Paula F. Ypma, Britta A.P. Laros-van Gorkom, Marten R. Nijziel, Pieter W. Kamphuisen, Eveline P. Mauser-Bunschoten, Goris Roosendaal, Douwe H. Biesma, Aad van der Lugt, Albert Hofman, Jacqueline C.M. Witteman, Michiel L. Bots, Roger E.G. Schutgens
Download PDF
https://doi.org/10.1161/ATVBAHA.111.238162
Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32:799-804
Originally published February 15, 2012
Attie Tuinenburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annemarieke Rutten
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maryam Kavousi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank W.G. Leebeek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paula F. Ypma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Britta A.P. Laros-van Gorkom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marten R. Nijziel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pieter W. Kamphuisen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eveline P. Mauser-Bunschoten
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Goris Roosendaal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douwe H. Biesma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aad van der Lugt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert Hofman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline C.M. Witteman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michiel L. Bots
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger E.G. Schutgens
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Sources of Funding
    • Disclosures
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Objective—Ischemic heart disease mortality is lower in hemophilia patients than in the general male population. As coagulation plays a role in the inflammatory pathways involved in atherogenesis, we investigated whether the clotting factor deficiency protects hemophilia patients from developing atherosclerosis.

Methods and Results—Coronary artery calcification, measured with multidetector-row computed tomography, was compared between 42 men, ≥59 years, with severe or moderate hemophilia A, and 613 nonhemophilic men from the Rotterdam Study, a prospective population-based study. None of the study subjects were HIV infected or had a history of cardiovascular disease. Coronary artery calcification was quantified by calculating the Agatston score and calcification mass. Data were analyzed using linear regression. Mean difference (β) of the natural log–transformed Agatston score between men with and without hemophilia was 0.141 (95% CI −0.602 to 0.885, P=0.709). Results did not change after adjustment for age, body mass index, hypercholesterolemia, hypertension, and use of antidiabetic medication (β=0.525, 95% CI −0.202 to 1.252, P=0.157). Comparable results were found for calcification mass.

Conclusion—The extent of coronary artery atherosclerosis is comparable between elderly men with and without hemophilia. Results from this study underline the importance of screening and treating atherosclerosis risk factors in hemophilia patients.

  • atherosclerosis
  • coagulation
  • coronary heart disease
  • hemophilia
  • imaging

Introduction

Since the introduction of clotting factor concentrates, life expectancy of hemophilia patients has increased and now approaches that of the general male population.1,2 Consequently, aging hemophilia patients not only experience medical issues associated with their congenital bleeding disorder but are increasingly confronted with age-related comorbidities, including ischemic cardiovascular disease (CVD).3,4 Interestingly, cohort studies reported a reduced mortality due to ischemic heart disease (IHD) in hemophilia patients as compared with the general male population.1,2

Several mechanisms explaining this observation have been considered.5 Rosendaal et al6 showed that differences in the prevalence of cardiovascular risk factors between men with and without hemophilia could not account for the lower IHD mortality in hemophilia patients. Another, very plausible, explanation could be that the hypocoagulable state of hemophilia patients has a protective effect on thrombus formation, which precipitates myocardial infarction.7,8 In this study, we focused on the hypothesis that hemophilia patients develop less atherosclerosis than men without hemophilia. Atherosclerosis is an inflammatory disease, which develops in response to injury of the endothelium.9,10 Current evidence supports considerable cross-talk between thrombosis and the inflammatory pathways involved in the different stages of atherogenesis (eg, plaque initiation and expansion, and fibrous cap degradation and rupture).11,12 Thrombin is the main effector of the coagulation cascade and links coagulation to inflammation by having proinflammatory effects, via protease-activated receptors, on the cells involved in atherogenesis.11,12 Activation of prothrombin into thrombin is less in hemophilia patients as compared with nonhemophilic subjects. This might reduce the stimulation of proinflammatory pathways supporting atherogenesis. This is in line with the observation that elevated factor VIII (FVIII) levels have been positively associated with atherosclerosis.13,14

As compared with apolipoprotein E–deficient mice, apolipoprotein E and FVIII double-deficient mice developed considerably fewer early-stage atherosclerotic lesions, which were almost devoid of fibrinogen, fibrin and platelets. At a later stage, FVIII deficiency only delayed plaque progression.15 Recently, Fabri et al16 showed that FVIII deficiency was associated with an antiatherosclerotic phenotype in apolipoprotein E–deficient mice. However, FVIII deficiency did not influence the degree of atherosclerosis in mice lacking the low-density lipoprotein receptor, a model more resembling the human situation.16 Conflicting results have also been reported by studies comparing intima-media thickness (IMT) between hemophilia patients and nonhemophilic subjects.17–21 This could be due to heterogeneous study populations including patients with other bleeding disorders than hemophilia, low mean ages, not well chosen or not well defined comparison populations, and variability in tests and outcome parameters.

With multidetector-row computed tomography (MDCT), the amount of coronary artery calcification (CAC) can be assessed noninvasively. Because CAC is correlated with the amount of coronary atherosclerotic plaque in histopathologic studies, it can be used as a measure of the extent of coronary artery atherosclerosis.22,23 In this cross-sectional study, we investigated the influence of FVIII deficiency on atherosclerosis by comparing CAC between elderly hemophilia A patients and the general male population.

Methods

Male patients, ≥59 years, with severe (FVIII activity <1%) or moderate (FVIII activity 1% to 5%) hemophilia A, HIV-negative, asymptomatic for CVD, and treated at 1 of the participating Dutch hemophilia treatment centers (University Medical Center Utrecht, Erasmus University Medical Center, HagaZiekenhuis, Radboud University Nijmegen Medical Centre, Maxima Medical Center, and Academic Medical Center) were eligible for this study. Symptomatic CVD comprised a history of myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, atrial fibrillation, or stroke. All hemophilia patients were white and underwent study examinations between November 2009 and February 2011.

Comparison data on CAC and cardiovascular risk factors were obtained from the Rotterdam Study, a prospective population-based study with the aim of assessing the occurrence of chronic diseases in an aging population and to clarify their determinants.24 In 1990, all inhabitants of a suburb of Rotterdam, the Netherlands, aged ≥55 years, were invited, and 7983 agreed to participate (78%). In 2000, the cohort was extended with 3011 subjects. From September 2003 until February 2006, all participants who completed a center visit (the fourth visit for the original cohort and the second visit for the extended cohort) were invited to undergo an MDCT scan of the coronary arteries.25 Data on CAC were available for 2482 people (age range, 59–98 years). For the current study, white males from the Rotterdam Study without known HIV-infection, bleeding disorders, or symptomatic CVD before scanning were selected. The same definition for symptomatic CVD as in hemophilia patients was used. All eligible males from the Rotterdam Study matching the age of 1 of the hemophilia patients were included.

This study was approved by the Medical Ethics Committee of the University Medical Center Utrecht ( Utrecht, the Netherlands). The Rotterdam Study was approved by the Medical Ethics Committee and the Radiation Protection Unit of the Erasmus University Medical Center (Rotterdam, the Netherlands). All participants provided written informed consent.

During the study visit of hemophilia patients to the University Medical Center Utrecht, characteristics of hemophilia were assessed. In addition, information on medical history, family history of CVD, medication use, and smoking behavior was collected. In the Rotterdam Study, this information was also collected. In both hemophilia patients and people included in the Rotterdam Study, systolic and diastolic blood pressures were measured at the right brachial artery in a sitting position. The mean of 2 consecutive measurements was used. Hypertension was defined as a systolic blood pressure of ≥140 mm Hg, a diastolic blood pressure ≥90 mm Hg, or use of antihypertensive medication. Height and weight were measured, and body mass index was calculated as weight divided by height squared (kg/m2). Total cholesterol, high-density lipoprotein cholesterol, triglycerides, and glucose were measured in blood samples from both hemophilia patients and Rotterdam Study subjects. Low-density lipoprotein cholesterol was calculated using Friedewald's equation. Hypercholesterolemia was defined as a total cholesterol level ≥6.5 mmol/L or use of lipid-lowering medication.

Ten-year risk of coronary heart disease (CHD) was calculated for all subjects, using the Framingham Point Scores as recommended in the third report of the National Cholesterol Education Program.26 Points were assigned to categorized risk factors and summed. The summary score corresponds to a 10-year predicted risk of CHD (nonfatal myocardial infarction or fatal CHD) and can be classified into low (<10%), intermediate (10% to 20%), and high (>20%) risk categories.26

Hemophilia patients were scanned with a 128×2 detector computed tomography scanner (Brilliance iCT, Philips Healthcare, Cleveland, OH) at the University Medical Center Utrecht. The cardiac scan reached from the tracheal bifurcation to the apex of the heart. Within a single breath hold, an overlapping data set of 3-mm-thick slices was acquired (scan parameters: 128×0.625-mm collimation, 120 kVp, 30–80 mAs [depending on weight], prospective ECG triggering in mid-diastole). Quantification of CAC was performed by a trained scan reader (A.R.), blinded to the clinical data, using software for calcium scoring (Heartbeat-CS, EBW, Philips Medical Systems, Best, the Netherlands). All voxels with an attenuation of ≥130 Hounsfield units were highlighted by the software. Atherosclerotic calcifications in the left main, the left anterior descending, the left circumflex, and the right coronary arteries were manually identified by the scan reader. For each calcified lesion, the Agatston score was calculated as the product of the area of a calcified lesion, and a factor was assigned according to the maximum attenuation value of the lesion.27 The total Agatston score was calculated by adding up the scores of each individual lesion.27 Because of the limited interscan reproducibility of the Agatston score, an algorithm quantifying the calcification mass, with lower interscan variability, was introduced.28–31 Calcification mass (mg hydroxyapatite) was calculated as the volume of a calcification times the mean computed tomography number multiplied by a calibration factor c (mg/Hounsfield units×cm3).29

The scan protocol and analyses of calcification in the Rotterdam Study have been described in detail previously.25,32 In short, imaging was performed with a 16-slice (n=152) or 64-slice (n=461) MDCT scanner (SOMATON Sensation 16 or 64, Siemens, Forcheim, Germany). Within a single breath hold, 3-mm-thick slices were acquired (scan parameters: 12×1.5-mm [16-slice scanner] or 32×0.6-mm [64-slice scanner] collimation, 120 kVp, prospective ECG triggering in mid-diastole). Two trained scan readers, blinded to the clinical data, determined CAC with dedicated software (Syngo Calcium Scoring, Siemens) that uses the same algorithms for the Agatston score and calcification mass as described above. To investigate whether the Agatston score, obtained with the software and by the scan readers of the Rotterdam Study, could be reproduced with the software and by the scan reader at the University Medical Center Utrecht, the same investigator (A.R.) rescored the CAC of 19 Rotterdam Study scans.

Spearman's rank correlation coefficient was calculated to assess reproducibility between the software and scan readers of the Rotterdam Study and the software and scan reader at the University Medical Center Utrecht. The distributions of the Agatston score and calcification mass were highly skewed, and therefore, natural log–transformed (ln-transformed) values were used (eg, ln[Agatston score +1]) when analyzing these outcome parameters linearly. The crude association between having hemophilia and the ln-transformed Agatston score was calculated, using univariate linear regression analysis. Imbalances of cardiovascular risk factors across exposure groups were assessed. Then, every potential confounder was included in a bivariate linear regression model, and the percentage change of the crude regression coefficient was assessed. The covariates age, body mass index, hypercholesterolemia, hypertension, and use of antidiabetic medication changed the crude regression coefficient the most (>20%) and were included in a multivariate linear regression model. The association between having hemophilia and the ln-transformed calcification mass was adjusted for the same confounders. Differences between the ln-transformed Agatston score and calcification mass between patients with severe (FVIII activity <1%) and moderate (FVIII activity 1% to 5%) and between patients using <50 000 U of clotting factor concentrate per year and patients using >50 000 U of clotting factor concentrate per year were assessed using the independent t test. As proposed by Rumberger et al,33 Agatston scores were divided into 4 categories: absent-minimal (0–9), mild (10–99), moderate (100–399), and severe (≥400) degrees of calcification. Using χ2 tests, differences in Agatston score categories and 10-year CHD risk categories between men with and without hemophilia were assessed. Analyses were performed using SPSS 17.0 for Windows (SPSS, Inc, Chicago, IL).

Results

Sixty eligible hemophilia patients were invited, and 42 agreed to participate (70%). Half of the hemophilia patients had a FVIII activity of <1% (Table 1). Most hemophilia patients were treated on demand and used <50 000 U of clotting factor concentrate per year. Fourteen (33.3%) patients were infected with hepatitis C, whereas 16 (38.1%) patients had been successfully treated or had spontaneously cleared the virus (Table 1). The selection procedure described earlier resulted in a comparison group of 613 nonhemophilic men.

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of Hemophilia Patients

Cardiovascular risk factors are described in Table 2. Mean age of the study population was 66.5 years (standard deviation 4.6). In both hemophilia patients and nonhemophilic men, age ranged from 59 to 77 years. As compared with men without hemophilia, more hemophilia patients smoked. Mean body mass index, mean total cholesterol levels, and the proportion of subjects with hypercholesterolemia were higher in the comparison group than in hemophilia patients. Of 42 hemophilia patients, 18 (42.9%) used antihypertensive medication and 32 (76.2%) were hypertensive, whereas only 26.1% of the comparison population used antihypertensive medication and 65.1% were hypertensive. Mean blood pressure was comparable between the 2 study groups. No differences in 10-year CHD risk category distributions between men with and without hemophilia were found (P=0.554).

View this table:
  • View inline
  • View popup
Table 2.

Cardiovascular Risk Factors

Agatston scores obtained in the Rotterdam Study could be reproduced by the software and scan reader at the University Medical Center Utrecht (Spearman's rank correlation coefficient 0.986, P<0.001). CAC outcomes are summarized in Table 3. No differences in Agatston score category distributions between hemophilia patients and nonhemophilic males were found (P=0.792). The proportion of subjects having an Agatston score of 1000 or more was comparable between men with and without hemophilia (11.9% versus 9.8%, respectively).

View this table:
  • View inline
  • View popup
Table 3.

Coronary Artery Calcification Outcomes

The mean ln-transformed Agatston score and calcification mass were slightly higher in hemophilia patients as compared with nonhemophilic men. Univariate linear regression analyses showed no association between the ln-transformed Agatston score and hemophilia (Table 4). Mean difference (β) of the ln-transformed Agatston score between men with and without hemophilia was 0.141 (95% CI −0.602 to 0.885, P=0.709). Results did not change after multivariate adjustment for age, body mass index, hypercholesterolemia, hypertension, and use of antidiabetic medication (β=0.525, 95% CI −0.202 to 1.252, P=0.157). Comparable results were found for calcification mass (Table 4). When comparing the ln-transformed Agatston score and calcification mass between patients with severe (FVIII activity <1%) and moderate (FVIII activity 1% to 5%) hemophilia, no differences were observed (mean difference −0.983, 95% CI −2.404 to 0.439, P=0.170; and mean difference −0.871, 95% CI −2.009 to 0.267, P=0.130, respectively). No statistically significant difference between the amount of clotting factor concentrate usage and the extent of CAC was found (Agatston score P=0.066; calcification mass P=0.052).

View this table:
  • View inline
  • View popup
Table 4.

Regression Coefficients Describing the Association Between the Natural Log–Transformed Agatston Score and Calcification Mass and Having Hemophilia

Discussion

In this study, we found no evidence for a protective effect of congenital FVIII deficiency on the development of CAC measured with MDCT.

Previous studies, using B-mode ultrasonography to compare carotid and femoral IMT between hemophilia patients and nonhemophilic subjects, reported conflicting results.17–21 Srámek et al21 and Sartori et al20 found no differences in IMT, whereas 3 other studies17–19 did show a lower IMT, fewer atherosclerotic plaques, or both in hemophilia patients. In these studies, patients were relatively young; mean age ranged from 40 to 58 years. Possibly, atherosclerotic burden of the study population was so low that it complicated the detection of differences between the groups. A major disadvantage in most studies is the heterogeneous study population, combining patients with severe, moderate, and mild hemophilia A or B or von Willebrand disease.17,18,20,21 Clotting factors VIII and IX and von Willebrand factor play different roles in the development of atherosclerosis.12,34 Combining these disorders in 1 study might result in masking a possible relationship between 1 of the disorders and atherosclerosis. Unfortunately, sample sizes are too small for valid subgroup analyses. Moreover, comparison groups were not well chosen and, in some, not well described.17–21 In addition, confounding was not accounted for in the analyses. These factors make interpretation of the results difficult.

In the current study, only patients with a residual FVIII activity ≤5% were included. If a protective effect of FVIII deficiency on the development of atherosclerosis exists, it can be expected to be most pronounced in patients with severe or moderate hemophilia A. The hemophilia study population had a mean age of 65 years, thereby having a high probability of having developed atherosclerosis. We excluded HIV-positive patients because most of them are treated with highly active antiretroviral therapy, which influences CVD risk.35 A well-defined, large sample from the Dutch general male population was used for comparison.

Hemophilia patients were more often hypertensive as compared with men without hemophilia. This result is in accordance with other studies.6,36–39 However, the underlying mechanism of this observation is unknown. Mean total cholesterol levels and the proportion of subjects with hypercholesterolemia were lower in the hemophilia patients than in the comparison group, which is consistent with the results of Rosendaal et al6 This could be explained by the association between chronic hepatitis C infection and a favorable lipoprotein profile.40 We calculated the 10-year CHD risk, using the Framingham Point Scores, and found no differences in risk category distributions between men with and without hemophilia.26 This prediction algorithm is based on and developed for the general population.41 Consequently, true risks for the hemophilia study population will be different from the calculated risks. However, to compare a summary of the prevalence of cardiovascular risk factors between hemophilia patients and the general male population, in a scientific setting, the Framingham Point Scores can be used. The role of the available cardiovascular risk prediction algorithms in hemophilia patients in a clinical setting is less clear.

The lack of evidence for a lower extent of coronary artery atherosclerosis in hemophilia patients makes that alternative hypotheses, explaining the reduced IHD mortality in these patients, should be considered or reconsidered. In 1990, Rosendaal et al6 concluded that only a fraction of the reduced IHD mortality in hemophilia patients as compared with the general male population could be explained by differences in risk factor prevalence. Since then, the elderly hemophilia patient population has expanded, and competing risks due to HIV and hepatitis C infection are now less important. Therefore, large prospective studies are needed to reassess the current prevalence of risk factors and their influence on CVD risk in hemophilia patients. As mentioned before, a very plausible explanation would be that the hypocoagulable state of hemophilia patients has a protective effect on thrombus formation. Possibly, hemophilia patients more often develop a mural thrombus on plaque rupture than a fatal occlusive thrombus as compared with nonhemophilic men.5 As several cohort studies investigated IHD death in hemophilia patients, only 1 study compared IHD prevalence between men with and without hemophilia.42 The authors found that the rate of IHD hospital discharges among hemophilia patients 65 years and older was nearly 30% lower than that of nonhemophilic males. This might imply that hemophilia patients experience plaque rupture less often or that they have a “silent ” plaque rupture more often than nonhemophilic males do. When plaque rupture or erosion is silent and thrombosis does not lead to arterial occlusion, platelets and the thrombotic response are important in the process of plaque progression.43 Degranulating platelets release platelet-derived growth factor and transforming growth factor-β, which cause a fibrotic healing response, leading to increased collagen accumulation, smooth muscle cell proliferation and accelerated progressive luminal narrowing.43 This might explain the comparable amount of atherosclerosis found in the current study. The risk of plaque rupture mainly depends on plaque composition.44,45 Vulnerable plaques have thin or eroded fibrous caps that overlay large lipid cores and contain a lot of inflammatory cells.44,45 Hemophilia patients might develop less vulnerable plaques. Plaque composition can be investigated with magnetic resonance imaging.46 In addition, markers of plaque vulnerability, such as matrix metalloproteinases and fibrin, can be targeted with antibodies and visualized with molecular magnetic resonance imaging.46

Some limitations of this study need to be discussed. Only 42 patients with hemophilia A were included, which may have affected the results. However, no tendency for a difference in the extent of CAC between men with and without hemophilia was observed. Therefore, we think it is unlikely that larger numbers would have changed the results. Hemophilia patients receive prophylactic or on-demand treatment with clotting factor concentrates. If a protective effect of FVIII deficiency exists, it could have been influenced by this treatment. However, patients with severe hemophilia temporarily become mild hemophiliacs after prophylactic treatment, and FVIII activity decreases to ≤5% before the next prophylactic treatment in many of them. Thus, FVIII activity is not normalized. In addition, during a large part of the lives of elderly hemophilia patients, treatment with clotting factor concentrates was not (regularly) available. On the other hand, the hemophilia patient who is treated for its disease is the patient we see in our clinic every day, and the cohort studies showing a lower IHD mortality are based on this population. It is not clear whether hepatitis C infection is positively related to atherosclerosis, as studies investigating this relation by measuring IMT reported conflicting results.47,48 Therefore, patients with past or current hepatitis C infection were not excluded. Different MDCT scanners were used to assess CAC in men with and without hemophilia, and different scan readers performed CAC quantification. However, a standard calcium-scoring acquisition protocol with 3-mm-thick slices and prospective ECG triggering was used in both groups. In addition, the quantification process has been largely automated, algorithms for calculating the Agatston score and calcification mass have been standardized, and quantification was shown to be reproducible between centers.

In conclusion, the amount of coronary artery atherosclerosis is comparable between elderly patients with hemophilia A and men from the general population. Despite the relative protection against IHD mortality, the incidence of ischemic CVD in hemophilia patients is increasing as life expectancy now approaches that of the general population.1,2,4 Treatment of these patients is complex, because of the delicate equilibrium between bleeding and thrombosis, and evidence-based treatment guidelines are lacking.3,49 Results from this study underline the importance of screening and treating atherosclerosis risk factors to minimize the risk of cardiovascular events in hemophilia patients.

Sources of Funding

This work was supported by the CSL Behring Prof Heimburger Award 2010. The Rotterdam Study is funded by Erasmus University Medical Center and Erasmus University, Rotterdam; Netherlands Organization for Health Research and Development; the Research Institute for Diseases in the Elderly; the Netherlands Heart Foundation; the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. Dr Witteman was supported by the Netherlands Organization for Scientific Research (Vici 918.76.619).

Disclosures

None.

Acknowledgments

We thank the hemophilia patients for participating in this study. The Rotterdam Study investigators are grateful to the participants and staff from the Rotterdam Study, the participating general practitioners, and the pharmacists.

  • Received August 31, 2011.
  • Accepted December 2, 2011.
  • © 2012 American Heart Association, Inc.

References

  1. 1.↵
    1. Darby SC,
    2. Kan SW,
    3. Spooner RJ,
    4. Giangrande PL,
    5. Hill FG,
    6. Hay CR,
    7. Lee CA,
    8. Ludlam CA,
    9. Williams M
    . Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007; 110: 815– 825.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Plug I,
    2. van der Bom JG,
    3. Peters M,
    4. Mauser-Bunschoten EP,
    5. de Goede-Bolder A,
    6. Heijnen L,
    7. Smit C,
    8. Willemse J,
    9. Rosendaal FR
    . Mortality and causes of death in patients with hemophilia, 1992–2001: a prospective cohort study. J Thromb Haemost. 2006; 4: 510– 516.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Mannucci PM,
    2. Schutgens RE,
    3. Santagostino E,
    4. Mauser-Bunschoten EP
    . How I treat age-related morbidities in elderly persons with hemophilia. Blood. 2009; 114: 5256– 5263.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Mauser-Bunschoten EP,
    2. Fransen van de Putte DE,
    3. Schutgens RE
    . Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia. 2009; 15: 853– 863.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Tuinenburg A,
    2. Mauser-Bunschoten EP,
    3. Verhaar MC,
    4. Biesma DH,
    5. Schutgens RE
    . Cardiovascular disease in patients with haemophilia. J Thromb Haemost. 2009; 7: 247– 254.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Rosendaal FR,
    2. Briët E,
    3. Stibbe J,
    4. van Herpen G,
    5. Leuven JA,
    6. Hofman A,
    7. Vandenbroucke JP
    . Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol. 1990; 75: 525– 530.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Gui T,
    2. Reheman A,
    3. Funkhouser WK,
    4. Bellinger DA,
    5. Hagaman JR,
    6. Stafford DW,
    7. Monahan PE,
    8. Ni H
    . In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice. Thromb Res. 2007; 121: 225– 234.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Mizuno T,
    2. Sugimoto M,
    3. Matsui H,
    4. Hamada M,
    5. Shida Y,
    6. Yoshioka A
    . Visual evaluation of blood coagulation during mural thrombogenesis under high shear blood flow. Thromb Res. 2008; 121: 855– 864.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Libby P,
    2. Ridker PM,
    3. Hansson GK
    . Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009; 54: 2129– 2138.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Ross R
    . The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993; 362: 801– 809.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Coughlin SR
    . Thrombin signalling and protease-activated receptors. Nature. 2000; 407: 258– 264.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Croce K,
    2. Libby P
    . Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol. 2007; 14: 55– 61.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Pan WH,
    2. Bai CH,
    3. Chen JR,
    4. Chiu HC
    . Associations between carotid atherosclerosis and high factor VIII activity, dyslipidemia, and hypertension. Stroke. 1997; 28: 88– 94.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Tracy RP,
    2. Bovill EG,
    3. Yanez D,
    4. Psaty BM,
    5. Fried LP,
    6. Heiss G,
    7. Lee M,
    8. Polak JF,
    9. Savage PJ
    . Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1995; 15: 1269– 1279.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Khallou-Laschet J,
    2. Caligiuri G,
    3. Tupin E,
    4. Gaston AT,
    5. Poirier B,
    6. Groyer E,
    7. Urbain D,
    8. Maisnier-Patin S,
    9. Sarkar R,
    10. Kaveri SV,
    11. Lacroix-Desmazes S,
    12. Nicoletti A
    . Role of the intrinsic coagulation pathway in atherogenesis assessed in hemophilic apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2005; 25: e123– e126.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Fabri DR,
    2. de Paula EV,
    3. Costa DS,
    4. Annichino-Bizzacchi JM,
    5. Arruda VR
    . Novel insights into the development of atherosclerosis in hemophilia A mouse models. J Thromb Haemost. 2011; 9: 1556– 1561.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Bilora F,
    2. Dei RC,
    3. Girolami B,
    4. Casonato A,
    5. Zanon E,
    6. Bertomoro A,
    7. Girolami A
    . Do hemophilia A and von Willebrand disease protect against carotid atherosclerosis? A comparative study between coagulopathics and normal subjects by means of carotid echo-color Doppler scan. Clin Appl Thromb Hemost. 1999; 5: 232– 235.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Bilora F,
    2. Boccioletti V,
    3. Zanon E,
    4. Petrobelli F,
    5. Girolami A
    . Hemophilia A, von Willebrand disease, and atherosclerosis of abdominal aorta and leg arteries: factor VIII and von Willebrand factor defects appear to protect abdominal aorta and leg arteries from atherosclerosis. Clin Appl Thromb Hemost. 2001; 7: 311– 313.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Bilora F,
    2. Zanon E,
    3. Petrobelli F,
    4. Cavraro M,
    5. Prandoni P,
    6. Pagnan A,
    7. Girolami A
    . Does hemophilia protect against atherosclerosis? A case-control study. Clin Appl Thromb Hemost. 2006; 12: 193– 198.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Sartori MT,
    2. Bilora F,
    3. Zanon E,
    4. Varvarikis C,
    5. Saggiorato G,
    6. Campagnolo E,
    7. Pagnan A,
    8. Cella G
    . Endothelial dysfunction in haemophilia patients. Haemophilia. 2008; 14: 1055– 1062.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Srámek A,
    2. Reiber JH,
    3. Gerrits WB,
    4. Rosendaal FR
    . Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation. 2001; 104: 762– 767.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Rumberger JA,
    2. Simons DB,
    3. Fitzpatrick LA,
    4. Sheedy PF,
    5. Schwartz RS
    . Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation. 1995; 92: 2157– 2162.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Sangiorgi G,
    2. Rumberger JA,
    3. Severson A,
    4. Edwards WD,
    5. Gregoire J,
    6. Fitzpatrick LA,
    7. Schwartz RS
    . Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol. 1998; 31: 126– 133.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Hofman A,
    2. van Duijn CM,
    3. Franco OH,
    4. Ikram MA,
    5. Janssen HL,
    6. Klaver CC,
    7. Kuipers EJ,
    8. Nijsten TE,
    9. Stricker BH,
    10. Tiemeier H,
    11. Uitterlinden AG,
    12. Vernooij MW,
    13. Witteman JC
    . The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol. 2011; 26: 657– 686.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Elias-Smale SE,
    2. Odink AE,
    3. Wieberdink RG,
    4. Hofman A,
    5. Hunink MG,
    6. Krestin GP,
    7. Koudstaal PJ,
    8. Breteler MM,
    9. van der Lugt A,
    10. Witteman JC
    . Carotid, aortic arch and coronary calcification are related to history of stroke: the Rotterdam Study. Atherosclerosis. 2010; 212: 656– 660.
    OpenUrlCrossRefPubMed
  26. 26.↵
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143– 3421.
    OpenUrlFREE Full Text
  27. 27.↵
    1. Agatston AS,
    2. Janowitz WR,
    3. Hildner FJ,
    4. Zusmer NR,
    5. Viamonte M Jr.,
    6. Detrano R
    . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15: 827– 832.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Detrano R,
    2. Kang X,
    3. Mahaisavariya P,
    4. Tang W,
    5. Colombo A,
    6. Molloi S,
    7. Garner D,
    8. Nickerson S
    . Accuracy of quantifying coronary hydroxyapatite with electron beam tomography. Invest Radiol. 1994; 29: 733– 738.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Hoffmann U,
    2. Siebert U,
    3. Bull-Stewart A,
    4. Achenbach S,
    5. Ferencik M,
    6. Moselewski F,
    7. Brady TJ,
    8. Massaro JM,
    9. O'Donnell CJ
    . Evidence for lower variability of coronary artery calcium mineral mass measurements by multi-detector computed tomography in a community-based cohort: consequences for progression studies. Eur J Radiol. 2006; 57: 396– 402.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Hong C,
    2. Bae KT,
    3. Pilgram TK
    . Coronary artery calcium: accuracy and reproducibility of measurements with multi-detector row CT: assessment of effects of different thresholds and quantification methods. Radiology. 2003; 227: 795– 801.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Ulzheimer S,
    2. Kalender WA
    . Assessment of calcium scoring performance in cardiac computed tomography. Eur Radiol. 2003; 13: 484– 497.
    OpenUrlPubMed
  32. 32.↵
    1. Odink AE,
    2. van der Lugt A,
    3. Hofman A,
    4. Hunink MG,
    5. Breteler MM,
    6. Krestin GP,
    7. Witteman JC
    . Risk factors for coronary, aortic arch and carotid calcification; The Rotterdam Study. J Hum Hypertens. 2010; 24: 86– 92.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Rumberger JA,
    2. Brundage BH,
    3. Rader DJ,
    4. Kondos G
    . Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999; 74: 243– 252.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Theilmeier G,
    2. Michiels C,
    3. Spaepen E,
    4. Vreys I,
    5. Collen D,
    6. Vermylen J,
    7. Hoylaerts MF
    . Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood. 2002; 99: 4486– 4493.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Friis-Møller N,
    2. Thiébaut R,
    3. Reiss P,
    4. Weber R,
    5. Monforte AD,
    6. de Wit S,
    7. El-Sadr W,
    8. Fontas E,
    9. Worm S,
    10. Kirk O,
    11. Phillips A,
    12. Sabin CA,
    13. Lundgren JD,
    14. Law MG
    . Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010; 17: 491– 501.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Biere-Rafi S,
    2. Baarslag MA,
    3. Peters M,
    4. Kruip MJ,
    5. Kraaijenhagen RA,
    6. den Heijer M,
    7. Büller HR,
    8. Kamphuisen PW
    . Cardiovascular risk assessment in haemophilia patients. Thromb Haemost. 2011; 105: 274– 278.
    OpenUrlPubMed
  37. 37.↵
    1. Miesbach W,
    2. Alesci S,
    3. Krekeler S,
    4. Seifried E
    . Comorbidities and bleeding pattern in elderly haemophilia A patients. Haemophilia. 2009; 15: 894– 899.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Siboni SM,
    2. Mannucci PM,
    3. Gringeri A,
    4. Franchini M,
    5. Tagliaferri A,
    6. Ferretti M,
    7. Tradati FC,
    8. Santagostino E,
    9. von Mackensen S
    . Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Haemost. 2009; 7: 780– 786.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Walsh M,
    2. Macgregor D,
    3. Stuckless S,
    4. Barrett B,
    5. Kawaja M,
    6. Scully MF
    . Health-related quality of life in a cohort of adult patients with mild hemophilia A. J Thromb Haemost. 2008; 6: 755– 761.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Dai CY,
    2. Chuang WL,
    3. Ho CK,
    4. Hsieh MY,
    5. Huang JF,
    6. Lee LP,
    7. Hou NJ,
    8. Lin ZY,
    9. Chen SC,
    10. Hsieh MY,
    11. Wang LY,
    12. Tsai JF,
    13. Chang WY,
    14. Yu ML
    . Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol. 2008; 49: 9– 16.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Wilson PW,
    2. D'Agostino RB,
    3. Levy D,
    4. Belanger AM,
    5. Silbershatz H,
    6. Kannel WB
    . Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: 1837– 1847.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Kulkarni R,
    2. Soucie JM,
    3. Evatt BL
    . Prevalence and risk factors for heart disease among males with hemophilia. Am J Hematol. 2005; 79: 36– 42.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Libby P
    . Inflammation in atherosclerosis. Nature. 2002; 420: 868– 874.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Fayad ZA,
    2. Fuster V
    . Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res. 2001; 89: 305– 316.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Leiner T,
    2. Gerretsen S,
    3. Botnar R,
    4. Lutgens E,
    5. Cappendijk V,
    6. Kooi E,
    7. van Engelshoven J
    . Magnetic resonance imaging of atherosclerosis. Eur Radiol. 2005; 15: 1087– 1099.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Choudhury RP,
    2. Fisher EA
    . Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol. 2009; 29: 983– 991.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Mostafa A,
    2. Mohamed MK,
    3. Saeed M,
    4. Hasan A,
    5. Fontanet A,
    6. Godsland I,
    7. Coady E,
    8. Esmat G,
    9. El-Hoseiny M,
    10. Abdul-Hamid M,
    11. Hughes A,
    12. Chaturvedi N
    . Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut. 2010; 59: 1135– 1140.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Volzke H,
    2. Schwahn C,
    3. Wolff B,
    4. Mentel R,
    5. Robinson DM,
    6. Kleine V,
    7. Felix SB,
    8. John U
    . Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis. 2004; 174: 99– 103.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Schutgens RE,
    2. Tuinenburg A,
    3. Roosendaal G,
    4. Guyomi SH,
    5. Mauser-Bunschoten EP
    . Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia. 2009; 15: 952– 958.
    OpenUrlCrossRefPubMed
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Arteriosclerosis, Thrombosis, and Vascular Biology
March 2012, Volume 32, Issue 3
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Sources of Funding
    • Disclosures
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Coronary Artery Calcification in Hemophilia A
    Attie Tuinenburg, Annemarieke Rutten, Maryam Kavousi, Frank W.G. Leebeek, Paula F. Ypma, Britta A.P. Laros-van Gorkom, Marten R. Nijziel, Pieter W. Kamphuisen, Eveline P. Mauser-Bunschoten, Goris Roosendaal, Douwe H. Biesma, Aad van der Lugt, Albert Hofman, Jacqueline C.M. Witteman, Michiel L. Bots and Roger E.G. Schutgens
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32:799-804, originally published February 15, 2012
    https://doi.org/10.1161/ATVBAHA.111.238162

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Arteriosclerosis, Thrombosis, and Vascular Biology.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Coronary Artery Calcification in Hemophilia A
    (Your Name) has sent you a message from Arteriosclerosis, Thrombosis, and Vascular Biology
    (Your Name) thought you would like to see the Arteriosclerosis, Thrombosis, and Vascular Biology web site.
  • Share on Social Media
    Coronary Artery Calcification in Hemophilia A
    Attie Tuinenburg, Annemarieke Rutten, Maryam Kavousi, Frank W.G. Leebeek, Paula F. Ypma, Britta A.P. Laros-van Gorkom, Marten R. Nijziel, Pieter W. Kamphuisen, Eveline P. Mauser-Bunschoten, Goris Roosendaal, Douwe H. Biesma, Aad van der Lugt, Albert Hofman, Jacqueline C.M. Witteman, Michiel L. Bots and Roger E.G. Schutgens
    Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32:799-804, originally published February 15, 2012
    https://doi.org/10.1161/ATVBAHA.111.238162
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Epidemiology, Lifestyle, and Prevention
    • Epidemiology
  • Vascular Disease
    • Thrombosis
  • Imaging and Diagnostic Testing
    • Computerized Tomography (CT)

Arteriosclerosis, Thrombosis, and Vascular Biology

  • About ATVB
  • Instructions for Authors
  • AHA CME
  • Meeting Abstracts
  • Permissions
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Contact the Editorial Office:
email: atvb@atvb.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured